ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Pretreatment nutritional and inflammatory indices can affect tolerance and response to neoadjuvant chemotherapy (NAC) in locally advanced and early-stage HER2‑positive breast cancer. Markers that predict different outcomes for anthracycline‑containing versus anthracycline‑free regimens could help tailor personalized treatment. This study examined whether pre‑treatment nutritional and inflammatory indices can distinguish response and survival differences between 2 NAC regimens - ddAC‑THP versus TCHP - in HER2‑positive breast cancer. MATERIAL AND METHODS This single‑center retrospective cohort study included 112 women with HER2‑positive invasive breast cancer treated with ddAC‑THP (n=72) or TCHP (n=40). Baseline serum albumin, lymphocyte, neutrophil, monocyte, C‑reactive protein, and cholesterol levels were used to calculate CONUT, mGPS, CAR, NPS, and PNI. Pathological complete response (pCR) rates, treatment metrics, and overall survival (OS) were compared. RESULTS Baseline characteristics and pCR rates (ddAC‑THP: 55.6%; TCHP: 50.0%; P=0.71) were similar. TCHP patients showed better overall survival (97.5% vs 84.7%; P=0.02). CAR had the strongest ability to differentiate between regimens (AUC 0.76; 95% CI 0.67-0.84; P<0.001), while NPS showed inverse prediction (AUC 0.25; P<0.001). CONUT, mGPS, NLR, LMR, and PNI did not have significant predictive power. There was a trend toward better survival with TCHP, but it did not reach statistical significance (log-rank P=0.065). CONCLUSIONS CAR showed modest discriminative ability between treatment groups in this cohort, while other indices had limited utility. The anthracycline-free TCHP regimen was associated with better observed overall survival than ddAC-THP, although time-to-event analysis showed only a borderline difference in survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.